<DOC>
	<DOCNO>NCT02595216</DOCNO>
	<brief_summary>Prospective clinical study evaluate Profound efficiency Up 60 healthy adult volunteer , male female , 18 70 year old . All subject study receive single treatment submental area profound device ; subject return four follow- visit : 1 week post treatment , 1 , 3 6 month post treatment . Prior treatment , tissue treat injected tumescence local dermal infiltration solution accord protocol .</brief_summary>
	<brief_title>Treatment With Profound System Submental Laxity</brief_title>
	<detailed_description>This study Prospective clinical study evaluate Profound device submental laxity . Up total 60 healthy candidate , seek treatment submental laxity . Subjects receive one Profound treatment target dermal subcutaneous layer skin . Before treatment ( 15-20 minute ) tissue treat injected tumescence solution . Each subject follow additional four ( 4 ) post treatment visit</detailed_description>
	<criteria>1 . Subjects seek laxity treatment submental area 2 . Healthy female male subject age 18 70 year age 3 . Informed consent process complete signed consent 4 . Willing receive propose Profound treatment follow protocol 5 . For female subject : pregnant lactating ; 6. either postmenopausal , surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment ( i.e. , oral contraceptive , contraceptive implant , barrier method spermicide abstinence ) 7 . Willing photograph take treated area use deidentified evaluation , publication presentation 1 . Surgery procedure laxity last 6 month 2 . Pregnant plan become pregnant , give birth le 3 month ago , and/or breast feeding 3 . Known allergy lidocaine epinephrine antibiotic 4 . Active malignancy history malignancy past 5 year 5 . Having active electrical implant anywhere body , pacemaker internal defibrillator 6 . Suffering significant concurrent illness , cardiac disorder , diabetes ( type I II ) , lupus , porphyria , pertinent neurological disorder ( i.e . disease state opinion Physician would interfere anesthesia , treatment , heal process ) 7 . Having know anticoagulative thromboembolic condition take anticoagulation medication one week prior treatment course ( allow inclusion , temporary cessation use per subject 's physician discretion ) 8 . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication 9 . Suffering hormonal imbalance , whether related thyroid , pituitary , androgen 10 . History significant lymphatic drainage problem 11 . History cancer require lymph node biopsy dissection 12 . Suffering significant skin condition treat area inflammatory skin condition , include , limited , open laceration abrasion , hidradenitis , dermatitis treatment area prior treatment ( duration resolution per Investigator 's discretion ) treatment course 13 . History keloid scarring , abnormal wound heal / prone bruise 14 . History epidermal dermal disorder ( particularly involve collagen microvascularity ) , include collagen vascular disease vasculitic disorder 15 . Use isotretinoin ( AccutaneÂ® ) within 6 month treatment study 16 . Systemic corticosteroid therapy 6 month prior throughout course study 17 . Dysplastic nevi area treat 18 . Participation study another device drug within 3 month prior enrollment study , treatment wrinkle laxity involve 19 . Subject palpable lymphadenopathy visit . Standard palpation technique use 20 . Subjects history severe edema 21 . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>